BioCentury | Mar 23, 2021
Management Tracks

Brainard to succeed Hallal as AlloVir CEO; plus Illumina, NeoGenomics, Nordic Nanovector, Abeona, Delix and more

...AI Inc. Pontin served as senior adviser and senior partner at Flagship Pioneering. Rare disease and oncology play SpringWorks Therapeutics Inc. (NASDAQ:SWTX...
...Robert Kiss from VP to SVP of process and analytical development. Gunjan Ohri DCVC Bio Section 32 AlloVir Inc. Illumina Inc. SpringWorks Therapeutics Inc. NeoGenomics...
BioCentury | Mar 18, 2021
Deals

Led by ex-Springworks exec, Pyxis forges deal to gain access to Pfizer’s ADCs, platform tech

...creation of an externalization model for stalled programs. She was the founder and president of SpringWorks Therapeutics Inc....
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...he’s watching two other targeted oncology companies. SpringWorks Therapeutics Inc....
BioCentury | Dec 18, 2020
Management Tracks

Rim named CEO of Samsung Biologics as Sarepta unveils promotions; plus Coughlin, Iovance, SpringWorks and NodThera

...company Iovance Biotherapeutics Inc. (NASDAQ:IOVA) hired Jean-Marc Bellemin as CFO. He was EVP and CFO at Gritstone Oncology Inc. (NASDAQ:GRTS).SpringWorks Therapeutics Inc. (NASDAQ:SWTX...
...NALP3; CIAS1) – NLR family pyrin domain containing 3 Danielle Golovin Sarepta Therapeutics Inc. Iovance Biotherapeutics Inc. Gritstone Oncology Inc. SpringWorks Therapeutics Inc. NodThera...
BioCentury | Oct 27, 2020
Product Development

Oct. 26 Quick Takes: COVID trips up Spectrum’s Rolontis at FDA; plus Jazz-SpringWorks, Novartis’ iptacopan, Kantaro, Eternygen

...setbacks for the oncology company. Shares of Spectrum fell 11% to $3.40.Jazz takes rights to SpringWorks’...
...inhibitor program including PF-04457845 from SpringWorks Therapeutics Inc. (NASDAQ:SWTX), and plans to develop the therapy for post-traumatic stress disorder. SpringWorks...
...withdrawal and fear extinction. Jazz will also assume obligations owed to Pfizer Inc. (NYSE:PFE), which spun out SpringWorks...
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...Inc. (NASDAQ:BLUE), Surface Oncology Inc. (NASDAQ:SURF), Blueprint Medicines Corp. (NASDAQ:BPMC), Translate Bio Inc. (NASDAQ:TBIO) and SpringWorks Therapeutics Inc....
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

...Bio Inc. (NASDAQ: VIE), which spun out of AstraZeneca plc (LSE:AZN; NYSE:AZN) in 2018, and SpringWorks Therapeutics Inc....
...following its $172.6 million IPO in October, with a current valuation of about $1.5 billion. SpringWorks...
...later, this September, brought in $186.3 million in an IPO, at a $778.2 million valuation. SpringWorks...
BioCentury | Dec 17, 2019
Financial News

Cellestia plans Phase II for solid, blood cancers with $20M series B

...γ secretase to inhibit NOTCH signaling are in the clinic. The most advanced, nirogacestat from SpringWorks Therapeutics Inc....
BioCentury | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

...John Flavin, who will remain as an independent director. Sullivan was founder and president of SpringWorks Therapeutics Inc....
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...NASDAQ:STSA) 09/12/19 $82.5 $249.1 $249.2 0% 10x Genomics Inc. (NASDAQ:TXG) 09/12/19 $448.5 $3,718.6 $4,805.6 29% SpringWorks Therapeutics Inc....
Items per page:
1 - 10 of 34
BioCentury | Mar 23, 2021
Management Tracks

Brainard to succeed Hallal as AlloVir CEO; plus Illumina, NeoGenomics, Nordic Nanovector, Abeona, Delix and more

...AI Inc. Pontin served as senior adviser and senior partner at Flagship Pioneering. Rare disease and oncology play SpringWorks Therapeutics Inc. (NASDAQ:SWTX...
...Robert Kiss from VP to SVP of process and analytical development. Gunjan Ohri DCVC Bio Section 32 AlloVir Inc. Illumina Inc. SpringWorks Therapeutics Inc. NeoGenomics...
BioCentury | Mar 18, 2021
Deals

Led by ex-Springworks exec, Pyxis forges deal to gain access to Pfizer’s ADCs, platform tech

...creation of an externalization model for stalled programs. She was the founder and president of SpringWorks Therapeutics Inc....
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...he’s watching two other targeted oncology companies. SpringWorks Therapeutics Inc....
BioCentury | Dec 18, 2020
Management Tracks

Rim named CEO of Samsung Biologics as Sarepta unveils promotions; plus Coughlin, Iovance, SpringWorks and NodThera

...company Iovance Biotherapeutics Inc. (NASDAQ:IOVA) hired Jean-Marc Bellemin as CFO. He was EVP and CFO at Gritstone Oncology Inc. (NASDAQ:GRTS).SpringWorks Therapeutics Inc. (NASDAQ:SWTX...
...NALP3; CIAS1) – NLR family pyrin domain containing 3 Danielle Golovin Sarepta Therapeutics Inc. Iovance Biotherapeutics Inc. Gritstone Oncology Inc. SpringWorks Therapeutics Inc. NodThera...
BioCentury | Oct 27, 2020
Product Development

Oct. 26 Quick Takes: COVID trips up Spectrum’s Rolontis at FDA; plus Jazz-SpringWorks, Novartis’ iptacopan, Kantaro, Eternygen

...setbacks for the oncology company. Shares of Spectrum fell 11% to $3.40.Jazz takes rights to SpringWorks’...
...inhibitor program including PF-04457845 from SpringWorks Therapeutics Inc. (NASDAQ:SWTX), and plans to develop the therapy for post-traumatic stress disorder. SpringWorks...
...withdrawal and fear extinction. Jazz will also assume obligations owed to Pfizer Inc. (NYSE:PFE), which spun out SpringWorks...
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...Inc. (NASDAQ:BLUE), Surface Oncology Inc. (NASDAQ:SURF), Blueprint Medicines Corp. (NASDAQ:BPMC), Translate Bio Inc. (NASDAQ:TBIO) and SpringWorks Therapeutics Inc....
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

...Bio Inc. (NASDAQ: VIE), which spun out of AstraZeneca plc (LSE:AZN; NYSE:AZN) in 2018, and SpringWorks Therapeutics Inc....
...following its $172.6 million IPO in October, with a current valuation of about $1.5 billion. SpringWorks...
...later, this September, brought in $186.3 million in an IPO, at a $778.2 million valuation. SpringWorks...
BioCentury | Dec 17, 2019
Financial News

Cellestia plans Phase II for solid, blood cancers with $20M series B

...γ secretase to inhibit NOTCH signaling are in the clinic. The most advanced, nirogacestat from SpringWorks Therapeutics Inc....
BioCentury | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

...John Flavin, who will remain as an independent director. Sullivan was founder and president of SpringWorks Therapeutics Inc....
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...NASDAQ:STSA) 09/12/19 $82.5 $249.1 $249.2 0% 10x Genomics Inc. (NASDAQ:TXG) 09/12/19 $448.5 $3,718.6 $4,805.6 29% SpringWorks Therapeutics Inc....
Items per page:
1 - 10 of 34